CLRB — Cellectar Biosciences, Inc.

Summary of Cellectar Biosciences, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of December 31, 2025, cash and cash equivalents stood at $13.2 million, down from $23.3 million in 2024. The company raised $5.8 million in Q4 2025.
• Expenses: Research and development (R&D) expenses decreased to approximately $11.5 million in Q4 2025 from $26.6 million in 2024, attributed to the conclusion of patient enrollment in the CLOVER-WaM study. General and administrative (SG&A) expenses also fell to $11.5 million from $25.6 million due to reduced pre-commercialization efforts.
• Net Loss: The net loss for the year was $21.8 million, or $8.35 per share, a significant reduction from the $44.6 million loss in 2024.

2. Strategic Updates and Business Highlights

• Iapocine I-131: The company is on track to submit a conditional marketing authorization application in Europe in 2026, with potential approval as early as 2027. The drug has received Breakthrough Therapy designation from the FDA.
• Clinical Trials: Initiated a Phase 1b study of CLR125 for triple-negative breast cancer (TNBC) and made progress on CLR225, an alpha-emitting agent, with plans for a Phase 1 trial pending funding.
• Intellectual Property: Expanded its global patent estate, enhancing protection for its drug candidates and proprietary platform.
• Supply Chain: Strengthened supply partnerships for isotopes necessary for clinical development.

3. Forward Guidance and Outlook

• The company expects to achieve multiple value-creating milestones in 2026, including updates on clinical data and regulatory submissions.
• Anticipates presenting compelling data at major medical meetings, focusing on the twelve-month follow-up results for Iapocine I-131, which are expected to show improved durability and efficacy.

4. Bad News, Challenges, or Points of Concern

• Cash Burn: The significant decrease in cash reserves raises concerns about the sustainability of operations without additional funding.
• Regulatory Risks: While the company has made progress, the need for ongoing regulatory engagement and the requirement for a confirmatory study could delay market entry.
• Market Competition: The competitive landscape for cancer therapies remains intense, with established treatments posing challenges for new entrants.

5. Notable Q&A Insights

• Regulatory Pathway: Management confirmed that the same data package for the EMA submission can largely be used for the FDA submission, although there will be some differences in analysis.
• Enrollment Expectations: There is high interest from physicians and patients in participating in the upcoming confirmatory study, which is expected to facilitate enrollment.
• Market Size: The European market for second-line treatment is slightly larger than the U.S. market, with a potential patient population of around 13,000.
• Data Expectations: The twelve-month follow-up data is anticipated to show improvements in response rates and progression-free survival, which could bolster the drug's market positioning.

Overall, Cellectar Biosciences demonstrated significant progress in 2025, particularly with its lead asset, while also facing challenges related to cash reserves and regulatory hurdles. The outlook for 2026 appears positive, contingent on successful data presentations and regulatory approvals.